BioAge Labs Inc. BIOA 深 滬
等待開盤 10-23 09:30:00 美东时间
6.05
+0.750
+14.15%
華盛通- 最 高6.11
- 今 開5.69
- 成交量 227.45万股
- 最 低 5.65
- 昨 收 5.30
- 總市值 2.17亿
- 52周最高 23.85
- 市盈率 靜 --
- 換手率 6.34%
- 52周最低 2.88
- 委 比 -93.08%
- 總股本 3585.00万
- 歷史最高 26.62
- 量 比 8.75
- 振 幅 8.68%
- 歷史最低 0.156
- 每 手 1
- 風險率 5.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
今天 10:06
Citigroup Upgrades Bioage Labs to Buy, Raises Price Target to $10
Citigroup analyst Samantha Semenkow upgrades Bioage Labs (NASDAQ:BIOA) from Neutral to Buy and raises the price target from $5 to $10.
10-22 19:21
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanem...
10-14 13:14
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
BioCryst Pharmaceuticals has agreed to acquire Astria Therapeutics for approximately $700 million in enterprise value, with the aim of adding Astria's Phase 3 HAE drug candidate, navenibart, to its portfolio. The deal is expected to solidify double-digit growth for BioCryst's HAE division over the next decade and maintain profitability. Navenibart is a long-acting, injectable therapy with a differentiated dosing schedule, addressing unmet needs i...
10-14 11:00
Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors
Biomerica Inc. appoints Gary Huff as an independent board member, leveraging his extensive experience in diagnostics, healthcare, and leadership. Huff, former CEO of LabCorp Diagnostics, brings a proven track record of commercial success and strategic vision. Biomerica highlights his ability to drive growth and innovation, particularly in advancing its inFoods® IBS product, a diagnostic-guided therapy for irritable bowel syndrome showing promisin...
10-08 12:19
Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
STOCKHOLM, Oct. 6, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iq...
10-07 06:02
BioArctic’s Leqembi Iqlik Launches in U.S. for Alzheimer’s Maintenance
BioArctic AB Class B ( ($SE:BIOA.B) ) has shared an announcement. BioArctic AB’...
10-07 05:04
BioAge Labs files $250M mixed securities shelf
BioAge Labs (NASDAQ:BIOA) files $250M mixed securities shelf. This prospectus is not an offer to sell these securities. Filing More on Powell Industries: From Backlog Boom To Growth Bust Polygon Stead...
10-03 04:42
Leqembi® approved for the treatment of early Alzheimer's disease in Australia
STOCKHOLM, Sept. 24, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab...
09-24 14:56
BioArctic Founders to Divest Minor Shareholdings
BioArctic AB Class B ( ($SE:BIOA.B) ) has provided an update. BioArctic AB anno...
09-04 00:05
